This video brief features Dr. Atul Verma reporting from AHA 2025 in New Orleans. He discusses the OCEAN randomized trial, which evaluates the necessity of ongoing oral anticoagulation in patients with atrial fibrillation (AF) and elevated stroke risk following successful catheter ablation. Findings from this trial are expected to inform risk-based decision-making for long-term anticoagulation management in patients after ablation and guide updates to clinical practice guidelines.
advertisement
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Related
Overview
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
videoPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Show more- video
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Show more - video
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Show more - video
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Show more - video
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Show more - video
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more - video
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more - video
Highlights of the Latest Hypertension Guidelines
Show more - video
Clinical Perspective on New Therapies in Resistant Hypertension
Show more
Recommended
Details
Presenters
Related
Overview
This video brief features Dr. Atul Verma reporting from AHA 2025 in New Orleans. He discusses the OCEAN randomized trial, which evaluates the necessity of ongoing oral anticoagulation in patients with atrial fibrillation (AF) and elevated stroke risk following successful catheter ablation. Findings from this trial are expected to inform risk-based decision-making for long-term anticoagulation management in patients after ablation and guide updates to clinical practice guidelines.
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
- video
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Show more - video
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Show more - video
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Show more - video
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Show more - video
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Show more - video
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more - video
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more - video
Highlights of the Latest Hypertension Guidelines
Show more - video
Clinical Perspective on New Therapies in Resistant Hypertension
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?